MA44973A - Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison pd1 - Google Patents
Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison pd1Info
- Publication number
- MA44973A MA44973A MA044973A MA44973A MA44973A MA 44973 A MA44973 A MA 44973A MA 044973 A MA044973 A MA 044973A MA 44973 A MA44973 A MA 44973A MA 44973 A MA44973 A MA 44973A
- Authority
- MA
- Morocco
- Prior art keywords
- trimer
- fragment
- molecules including
- tnf family
- family ligand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169487.2A EP3243832A1 (fr) | 2016-05-13 | 2016-05-13 | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison pd1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44973A true MA44973A (fr) | 2021-04-07 |
Family
ID=56014831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044973A MA44973A (fr) | 2016-05-13 | 2017-05-11 | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison pd1 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20190185566A1 (fr) |
| EP (2) | EP3243832A1 (fr) |
| JP (1) | JP6801006B2 (fr) |
| KR (1) | KR20190004802A (fr) |
| CN (1) | CN109563146B (fr) |
| AR (1) | AR108453A1 (fr) |
| AU (1) | AU2017264548A1 (fr) |
| BR (1) | BR112018073289A2 (fr) |
| CA (1) | CA3023393A1 (fr) |
| CL (1) | CL2018003205A1 (fr) |
| CO (1) | CO2018012083A2 (fr) |
| CR (1) | CR20180538A (fr) |
| IL (1) | IL262843A (fr) |
| MA (1) | MA44973A (fr) |
| MX (1) | MX2018013675A (fr) |
| PE (1) | PE20190436A1 (fr) |
| PH (1) | PH12018502367A1 (fr) |
| RU (1) | RU2018143439A (fr) |
| SG (1) | SG11201810076WA (fr) |
| TW (1) | TW201805306A (fr) |
| WO (1) | WO2017194641A1 (fr) |
| ZA (1) | ZA201807581B (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3224275B1 (fr) | 2014-11-14 | 2020-03-04 | F.Hoffmann-La Roche Ag | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf |
| EP3973980A1 (fr) | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| WO2017055404A1 (fr) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anticorps bispécifiques spécifiques de pd1 et tim3 |
| US10526413B2 (en) | 2015-10-02 | 2020-01-07 | Hoffmann-La Roche Inc. | Bispecific antibodies specific for OX40 |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| AU2017380981B2 (en) | 2016-12-19 | 2025-01-30 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1BB (CD137) agonists |
| KR102692708B1 (ko) | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| WO2018127473A1 (fr) | 2017-01-03 | 2018-07-12 | F. Hoffmann-La Roche Ag | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| CN110536693B (zh) | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| CN110573528B (zh) | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 针对共刺激性tnf受体的双特异性抗原结合分子 |
| MY201482A (en) | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| WO2018187215A1 (fr) * | 2017-04-03 | 2018-10-11 | Merrimack Pharmaceuticals, Inc. | Molécules bispécifiques à titre d'agoniste de 4-1bb |
| JP6997209B2 (ja) | 2017-04-04 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｃｄ４０およびｆａｐに特異的に結合することができる新規な二重特異性抗原結合分子 |
| EP4516809A3 (fr) | 2017-04-05 | 2025-09-03 | F. Hoffmann-La Roche AG | Anticorps bispécifiques se liant spécifiquement à pd1 et lag3 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| SG11202007961QA (en) | 2018-04-13 | 2020-09-29 | Hoffmann La Roche | Her2-targeting antigen binding molecules comprising 4-1bbl |
| EP3820887A4 (fr) | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Variant de la protéine de fusion pd1-4-1bbl et procédés d'utilisation associés |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| WO2020070041A1 (fr) | 2018-10-01 | 2020-04-09 | F. Hoffmann-La Roche Ag | Molécules bispécifiques de liaison à l'antigène comprenant un clone anti-fap 212 |
| UA128001C2 (uk) | 2018-12-21 | 2024-03-06 | Ф. Хоффманн-Ля Рош Аг | Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули |
| CN110592140A (zh) * | 2019-09-30 | 2019-12-20 | 王清路 | Pd-1基因缺陷型pd-1-cart细胞制剂的制法 |
| WO2021084124A1 (fr) * | 2019-11-01 | 2021-05-06 | Ares Trading S.A. | Inhibition combinée de pd-1, tgfp et atm associée à une radiothérapie pour le traitement du cancer |
| CN114929734A (zh) * | 2020-01-09 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 新型含有4-1bbl三聚体的抗原结合分子 |
| AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
| EP4149964A2 (fr) * | 2020-05-15 | 2023-03-22 | Apogenix AG | Modulateurs immunitaires multi-spécifiques |
| BR112023001209A2 (pt) * | 2020-07-24 | 2023-02-14 | Hoffmann La Roche | Método para produzir um polipeptídeo de fusão-anticorpo-multímero |
| WO2023088876A1 (fr) * | 2021-11-16 | 2023-05-25 | Apogenix Ag | Modulateurs immunitaires multi-spécifiques |
| CN114984207B (zh) * | 2022-05-09 | 2024-01-26 | 浙江特瑞思药业股份有限公司 | 一种抗pd-1纳米抗体制剂 |
| CN114966046A (zh) * | 2022-05-10 | 2022-08-30 | 乘典(苏州)生物医药有限公司 | 一种检测血清中PD-1Ab21蛋白含量的方法 |
| CN116333110B (zh) * | 2022-12-13 | 2025-09-19 | 生工生物工程（上海）股份有限公司 | 一种特异性结合afp多肽的结合蛋白、肿瘤诊断试剂盒 |
| WO2025064498A1 (fr) * | 2023-09-18 | 2025-03-27 | The Trustees Of Columbia University In The City Of New York | Anticorps bispécifiques anti-cd45 x pd-1 et anti-cd43 x pd-1 modulés par affinité pour traiter le cancer et l'auto-immunité |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2388385B1 (fr) | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0368684B2 (fr) | 1988-11-11 | 2004-09-29 | Medical Research Council | Clonage de séquences d'immunoglobulines de domaines variables. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (fr) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Procédé pour fabriquer des anticorps humanisés |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (fr) | 1992-02-06 | 1993-08-19 | L.L. Houston | Proteine fixatrice biosynthetique pour marqueur du cancer |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| EP1332209B1 (fr) | 2000-09-08 | 2009-11-11 | Universität Zürich | Groupes de proteines a domaines de repetition comprenant des modules de repetition |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2463879C (fr) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Compositions de glycoproteine |
| CA2466279A1 (fr) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents modulant l'activite de cellules immunes et procedes d'utilisation associes |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| WO2004087754A1 (fr) | 2003-04-03 | 2004-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antagonistes a large spectre efficaces in vivo de la toxine d'un superantigene reposant sur l'interaction entre la molecule cd28 et le superantigene, et utilisations correspondantes |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| US20060235201A1 (en) * | 2003-02-06 | 2006-10-19 | Roman Kischel | Enduring T cell response |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| CA2531238C (fr) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2) |
| WO2005019255A1 (fr) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteines de la lipocaline lacrymale |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| EP1711196A4 (fr) | 2003-12-05 | 2011-09-14 | Bristol Myers Squibb Co | Inhibiteurs des recepteurs du facteur de croissance endothelial vasculaire de type 2 |
| EP1740615B1 (fr) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Anticorps anti-tgf-beta humanises |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CA2611861C (fr) | 2005-06-08 | 2017-11-28 | The Brigham And Women's Hospital, Inc. | Methodes et compositions pour le traitement d'infections persistantes |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| KR101523391B1 (ko) | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
| EP1958957A1 (fr) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins" |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2009014708A2 (fr) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation |
| WO2009024531A1 (fr) | 2007-08-17 | 2009-02-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthode de traitement et de diagnostic de malignités hématologiques |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
| KR101001360B1 (ko) | 2008-06-16 | 2010-12-14 | (주)기가레인 | 전자 기기의 접지에 전기적으로 연결되는 인쇄회로기판 |
| ES2538122T3 (es) | 2008-07-21 | 2015-06-17 | Apogenix Gmbh | Moléculas de una sola cadena de TNFSF |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| MX2011005691A (es) | 2008-11-28 | 2011-07-20 | Univ Emory | Metodos para el tratamiento de infecciones y tumores. |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| WO2011066342A2 (fr) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Inhibition simultanée de pd-l1/pd-l2 |
| EP2545078A1 (fr) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Anticorps pd-1 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2806021C (fr) | 2010-08-13 | 2019-05-21 | Roche Glycart Ag | Anticorps anti-fap et procedes d'utilisation |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| JP6047142B2 (ja) * | 2011-04-01 | 2016-12-21 | ウニヴェルズィテート シュトゥットガルト | 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CA2840018C (fr) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants d'anticorps monoclonaux immunomodulateurs humanises |
| PL3489254T3 (pl) * | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2015095423A2 (fr) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Polythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| EP3224275B1 (fr) * | 2014-11-14 | 2020-03-04 | F.Hoffmann-La Roche Ag | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf |
| WO2017055404A1 (fr) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anticorps bispécifiques spécifiques de pd1 et tim3 |
| EP3150636A1 (fr) * | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Anticorps multispécifiques tétravalents |
| WO2017194442A1 (fr) * | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Molécules de liaison à un antigène comprenant un ligand trimérique de la famille du tnf et un fragment de liaison à la ténascine |
-
2016
- 2016-05-13 EP EP16169487.2A patent/EP3243832A1/fr not_active Ceased
-
2017
- 2017-05-11 KR KR1020187036101A patent/KR20190004802A/ko not_active Ceased
- 2017-05-11 WO PCT/EP2017/061241 patent/WO2017194641A1/fr not_active Ceased
- 2017-05-11 AR ARP170101253A patent/AR108453A1/es unknown
- 2017-05-11 BR BR112018073289-3A patent/BR112018073289A2/pt not_active Application Discontinuation
- 2017-05-11 MA MA044973A patent/MA44973A/fr unknown
- 2017-05-11 RU RU2018143439A patent/RU2018143439A/ru not_active Application Discontinuation
- 2017-05-11 PE PE2018002326A patent/PE20190436A1/es unknown
- 2017-05-11 EP EP17725542.9A patent/EP3455248B1/fr active Active
- 2017-05-11 AU AU2017264548A patent/AU2017264548A1/en not_active Abandoned
- 2017-05-11 SG SG11201810076WA patent/SG11201810076WA/en unknown
- 2017-05-11 MX MX2018013675A patent/MX2018013675A/es unknown
- 2017-05-11 CA CA3023393A patent/CA3023393A1/fr not_active Abandoned
- 2017-05-11 JP JP2018559781A patent/JP6801006B2/ja active Active
- 2017-05-11 CN CN201780038363.6A patent/CN109563146B/zh active Active
- 2017-05-11 CR CR20180538A patent/CR20180538A/es unknown
- 2017-05-12 TW TW106115699A patent/TW201805306A/zh unknown
-
2018
- 2018-11-07 IL IL262843A patent/IL262843A/en unknown
- 2018-11-08 CO CONC2018/0012083A patent/CO2018012083A2/es unknown
- 2018-11-09 PH PH12018502367A patent/PH12018502367A1/en unknown
- 2018-11-12 ZA ZA2018/07581A patent/ZA201807581B/en unknown
- 2018-11-12 CL CL2018003205A patent/CL2018003205A1/es unknown
- 2018-11-13 US US16/189,041 patent/US20190185566A1/en not_active Abandoned
-
2022
- 2022-01-28 US US17/649,321 patent/US20230123178A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CO2018012083A2 (es) | 2018-11-22 |
| RU2018143439A3 (fr) | 2020-08-03 |
| AU2017264548A1 (en) | 2018-11-22 |
| CN109563146A (zh) | 2019-04-02 |
| WO2017194641A1 (fr) | 2017-11-16 |
| PE20190436A1 (es) | 2019-03-27 |
| TW201805306A (zh) | 2018-02-16 |
| EP3243832A1 (fr) | 2017-11-15 |
| EP3455248B1 (fr) | 2021-06-30 |
| JP2019524053A (ja) | 2019-09-05 |
| SG11201810076WA (en) | 2018-12-28 |
| MX2018013675A (es) | 2019-04-01 |
| IL262843A (en) | 2018-12-31 |
| BR112018073289A2 (pt) | 2019-03-19 |
| US20190185566A1 (en) | 2019-06-20 |
| CA3023393A1 (fr) | 2017-11-16 |
| ZA201807581B (en) | 2021-05-26 |
| CN109563146B (zh) | 2022-10-14 |
| CR20180538A (es) | 2019-01-10 |
| EP3455248A1 (fr) | 2019-03-20 |
| JP6801006B2 (ja) | 2020-12-16 |
| RU2018143439A (ru) | 2020-06-15 |
| US20230123178A1 (en) | 2023-04-20 |
| CL2018003205A1 (es) | 2019-01-18 |
| KR20190004802A (ko) | 2019-01-14 |
| PH12018502367A1 (en) | 2019-09-09 |
| AR108453A1 (es) | 2018-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44973A (fr) | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison pd1 | |
| MA53242A (fr) | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf | |
| EP3612218A4 (fr) | Protéines de liaison à un antigène anti-trem2 et leurs utilisations | |
| PT3176181T (pt) | Anticorpo monoclonal anti-ctla4 ou fragmento de ligação ao antigénio do mesmo, composição medicinal e utilização | |
| MA44670A (fr) | Protéines de liaison trispécifiques et/ou trivalentes | |
| SG11202100172XA (en) | Antibody molecules that bind cd137 and ox40 | |
| EP3328994A4 (fr) | Protéines de liaison d'antigène ciblant cd56 et leurs utilisations | |
| MA42821A (fr) | Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci | |
| MA55347A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
| HRP20260195T1 (hr) | Proteini koji vežu anti-tl1a antigen i njihova upotreba | |
| MA47113A (fr) | Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation | |
| EP3655432A4 (fr) | Protéines de liaison 1 | |
| IL258448A (en) | Antigen-binding proteins that activate the leptin receptor | |
| MA46917A (fr) | Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation | |
| EP3331564A4 (fr) | Constructions de liaison d'antigène se liant à des molécules cibles | |
| MA41313A (fr) | Anticorps de liaison de la protéine april modifiés | |
| MA42613A (fr) | Filtration en profondeur chargée de protéines de liaison à un antigène | |
| EP3719035A4 (fr) | Polypeptide comprenant un domaine de liaison à l'antigène et une section de transport | |
| IL272358B (en) | Antigen-binding proteins that antagonize leptin receptor | |
| IL258924A (en) | Humanized anti-dkk2 antibody and uses thereof | |
| KR20220016865A9 (ko) | 항원 결합 분자, 약학 조성물, 및 방법 | |
| ZA202001807B (en) | Il-5 antibody, antigen binding fragment thereof, and medical application therefor | |
| MA46753A (fr) | Protéines de liaison à l'antigène bispécifiques ou biparatopiques et utilisations de celles-ci | |
| EP3356833A4 (fr) | Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1) | |
| PT3269735T (pt) | Anticorpo antiesclerotina, fragmanto de ligação a antigénio e seus usos médicos |